

Hyun Cheol Chung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2836048/publications.pdf>

Version: 2024-02-01

365
papers

23,857
citations

26630
56
h-index

9861
141
g-index

368
all docs

368
docs citations

368
times ranked

23006
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	13.7	1,749
2	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	1.6	1,740
3	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet</i> , The, 2012, 379, 315-321.	13.7	1,422
4	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology</i> , The, 2020, 21, 1353-1365.	10.7	1,363
5	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	13.7	984
6	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.	10.7	943
7	Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1389-1396.	10.7	849
8	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 859-870.	10.7	699
9	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1470-1478.	1.6	671
10	Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. <i>Nature Medicine</i> , 2013, 19, 329-336.	30.7	634
11	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	7.1	611
12	Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i> -Amplified Advanced Gastric Cancer in Asian Populations: TyTAN-A Randomized, Phase III Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2039-2049.	1.6	524
13	Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 241-250.	2.5	472
14	Trastuzumab emtansine versus taxane use for previously treated <i>HER2</i> -positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology</i> , The, 2017, 18, 640-653.	10.7	383
15	Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. <i>PLoS Genetics</i> , 2009, 5, e1000676.	3.5	354
16	The KEYNOTE-811 trial of dual PD-1 and <i>HER2</i> blockade in <i>HER2</i> -positive gastric cancer. <i>Nature</i> , 2021, 600, 727-730.	27.8	335
17	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
18	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198.	5.1	288

#	ARTICLE	IF	CITATIONS
19	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 234-247.	10.7	268
20	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 618-627.	1.1	254
21	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731.	12.1	197
22	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	5.3	181
23	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 319-328.	2.5	160
24	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
25	Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 498-507.	2.8	139
26	Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8506-8506.	1.6	131
27	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	2.6	124
28	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	3.7	122
29	Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4007-LBA4007.	1.6	119
30	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 946-953.	4.2	117
31	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	2.4	117
32	A randomized phase II trial of S-1-oxaliplatin versus capecitabine+oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , 2012, 48, 518-526.	2.8	116
33	Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. <i>BMC Genomics</i> , 2012, 13, 348.	2.8	114
34	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	7.0	107
35	Inhibition of Gastric Cancer Invasion and Metastasis by <i>PLA2G2A</i> , a Novel β -Catenin/TCF Target Gene. <i>Cancer Research</i> , 2008, 68, 4277-4286.	0.9	103
36	Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. <i>Gut</i> , 2021, 70, 829-837.	12.1	94

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.. Journal of Clinical Oncology, 2019, 37, 4079-4079.	1.6	94
38	Prevalence and prognostic implications of psychological distress in patients with gastric cancer. BMC Cancer, 2017, 17, 283.	2.6	93
39	AMPK β Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer. Cancer Research, 2012, 72, 2512-2521.	0.9	91
40	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2020, 26, 846-854.	7.0	90
41	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. Journal of Surgical Oncology, 2007, 95, 461-468.	1.7	89
42	Activation of Hypoxia-Inducible Factor-1 α Is Necessary for Lysophosphatidic Acid-Induced Vascular Endothelial Growth Factor Expression. Clinical Cancer Research, 2006, 12, 6351-6358.	7.0	85
43	Prediction of Recurrence of Early Gastric Cancer After Curative Resection. Annals of Surgical Oncology, 2009, 16, 1896-1902.	1.5	84
44	Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clinical Epigenetics, 2017, 9, 126.	4.1	82
45	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2017, 3, 235.	7.1	74
46	Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute. Annals of Surgical Oncology, 2007, 14, 2730-2737.	1.5	72
47	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 2022, 24, 997-1007.	1.2	72
48	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. Annals of Surgical Oncology, 2018, 25, 3222-3230.	1.5	69
49	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
50	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer, 2017, 81, 17-25.	2.8	64
51	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncology, 2021, 17, 1155-1164.	2.4	64
52	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. Journal of Clinical Oncology, 2017, 35, 2-2.	1.6	64
53	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Letters, 2004, 214, 215-224.	7.2	63
54	Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Research and Treatment, 2005, 90, 215-221.	2.5	63

#	ARTICLE	IF	CITATIONS
55	Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea. <i>Cancer Research and Treatment</i> , 2009, 41, 67.	3.0	63
56	High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. <i>Cancer</i> , 1997, 79, 878-883.	4.1	61
57	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
58	A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 204-210.	0.8	60
59	Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5514-5514.	1.6	60
60	Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5522-5522.	1.6	59
61	Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3-3.	1.6	58
62	Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-MMAC) scale: factor structure, reliability and validity. <i>Psycho-Oncology</i> , 2008, 17, 592-597.	2.3	57
63	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , 2016, 263, 96-102.	4.2	56
64	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4012-4012.	1.6	55
65	Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. <i>Genomics</i> , 2007, 89, 451-459.	2.9	54
66	<i>CD44-SLC1A2</i> Gene Fusions in Gastric Cancer. <i>Science Translational Medicine</i> , 2011, 3, 77ra30.	12.4	54
67	A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i>-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i>-Amplified Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2414-2423.	7.0	54
68	Intermediate Dose 5-Fluorouracil-Induced Encephalopathy. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 55-59.	1.3	53
69	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	7.0	53
70	Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 429-438.	1.5	52
71	The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 275-280.	1.7	52
72	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016, 7, 10547-10556.	1.8	52

#	ARTICLE	IF	CITATIONS
73	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer, 2018, 18, 1116.	2.6	51
74	Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 224-231.	1.5	50
75	An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients. Oncologist, 2007, 12, 622-630.	3.7	48
76	Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Research and Treatment, 2011, 125, 55-63.	2.5	48
77	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. Oncology, 2011, 80, 395-405.	1.9	48
78	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. Cancer Science, 2018, 109, 771-776.	3.9	48
79	Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death Ligand 1 Blockade Responses. Hepatology, 2021, 74, 1914-1931.	7.3	48
80	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget, 2016, 7, 44608-44620.	1.8	46
81	Evorpaccept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2021, 22, 1740-1751.	10.7	46
82	Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. , 1997, 79, 462-467.		45
83	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 143-153.	5.3	45
84	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight, 2016, 1, e87607.	5.0	44
85	The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. Annals of Surgical Oncology, 2010, 17, 3259-3268.	1.5	43
86	LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.. Journal of Clinical Oncology, 2021, 39, 94-94.	1.6	43
87	Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. International Journal of Cancer, 2005, 114, 484-489.	5.1	42
88	Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. International Journal of Hyperthermia, 2010, 26, 305-315.	2.5	42
89	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer, 2011, 117, 2050-2057.	4.1	42
90	A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures. PLoS Genetics, 2011, 7, e1002415.	3.5	42

#	ARTICLE	IF	CITATIONS
91	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066.	1.8	42
92	Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. <i>Clinical and Experimental Metastasis</i> , 1996, 14, 512-519.	3.3	41
93	FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective study. <i>Psychoneuroendocrinology</i> , 2012, 37, 1569-1576.	2.7	40
94	Coordination modes vs. antitumor activity: synthesis and antitumor activity of novel platinum(II) complexes of N-substituted amino dicarboxylic acids. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 98-104.	3.5	39
95	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1045-1056.	10.7	39
96	Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 175-181.	2.5	38
97	P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 65-72.	2.5	38
98	Molecular basis of the differences between normal and tumor tissues of gastric cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 1033-1040.	3.8	38
99	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013, 21, 1751-1759.	2.2	38
100	Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. <i>Experimental and Molecular Pathology</i> , 2016, 100, 287-293.	2.1	38
101	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 228-238.	4.1	38
102	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 587-601.	4.4	38
103	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4537-4537.	1.6	38
104	Prevalence and associated factors of psychological distress among Korean cancer patients. <i>General Hospital Psychiatry</i> , 2011, 33, 246-252.	2.4	37
105	A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. <i>Oncology</i> , 2011, 80, 142-150.	1.9	36
106	Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. <i>BMC Cancer</i> , 2013, 13, 394.	2.6	35
107	The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3074-3085.	4.1	35
108	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	7.0	35

#	ARTICLE	IF	CITATIONS
109	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Letters, 2010, 288, 124-132.	7.2	34
110	Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.. Journal of Clinical Oncology, 2021, 39, 321-321.	1.6	34
111	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget, 2017, 8, 113494-113501.	1.8	34
112	Multi-Institutional Phase II Study of Sâ€1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. Oncologist, 2007, 12, 543-554.	3.7	33
113	Bilateral Breast Cancer: Differential Diagnosis Using Histological and Biological Parameters. Japanese Journal of Clinical Oncology, 2007, 37, 487-492.	1.3	33
114	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. Journal of Clinical Oncology, 2016, 34, 6012-6012.	1.6	33
115	The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer, 2018, 21, 213-224.	5.3	32
116	A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467	1.6	31
117	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. Journal of Clinical Oncology, 2020, 38, 4503-4503.	1.6	31
118	Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain. Oncology, 1996, 53, 192-197.	1.9	30
119	Cyclic Induction of Senescence with Intermittent AZT Treatment Accelerates both Apoptosis and Telomere Loss. Breast Cancer Research and Treatment, 2005, 93, 227-236.	2.5	30
120	Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. BMC Genomics, 2007, 8, 305.	2.8	30
121	Gastrointestinal Stromal Tumor of the Rectum: An Analysis of Seven Cases. Surgery Today, 2007, 37, 455-459.	1.5	30
122	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. World Journal of Surgical Oncology, 2014, 12, 232.	1.9	30
123	Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1123-1130.	2.5	29
124	Gastric Cancer in Young Patients Who Underwent Curative Resection. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 45-48.	1.3	29
125	Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites. Cancer Research and Treatment, 2010, 42, 217.	3.0	29
126	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer, 2018, 119, 19-26.	6.4	28

#	ARTICLE	IF	CITATIONS
127	Angiogenic Factor Thymidine Phosphorylase Increases Cancer Cell Invasion Activity in Patients with Gastric Adenocarcinoma. <i>Molecular Cancer Research</i> , 2008, 6, 1554-1566.	3.4	27
128	Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 996-1003.	1.3	27
129	PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. <i>Oncology</i> , 2015, 88, 76-85.	1.9	27
130	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1197-1207.	2.3	27
131	Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 167-167.	1.6	27
132	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. <i>Cancer</i> , 2022, 128, 995-1003.	4.1	27
133	Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1901-1913.	2.5	26
134	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 95, 303-307.	0.6	26
135	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. , 2019, 7, 268.		26
136	A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1039-1039.	1.6	26
137	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4512-4512.	1.6	26
138	Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma¹. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 475-479.	2.8	25
139	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 517-526.	2.5	25
140	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. <i>JAMA Network Open</i> , 2019, 2, e198243.	5.9	25
141	Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6010-6010.	1.6	25
142	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. <i>Cancer Research and Treatment</i> , 2009, 41, 196.	3.0	25
143	Perioperative Blood Transfusions and Prognosis in Patients with Curatively Resected Locally Advanced Gastric Cancer. <i>Oncology</i> , 1995, 52, 170-175.	1.9	24
144	Forty-nine gastric cancer cell lines with integrative genomic profiling for development of a MET inhibitor. <i>International Journal of Cancer</i> , 2018, 143, 151-159.	5.1	24

#	ARTICLE	IF	CITATIONS
145	Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β 2 and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3202-3210.	7.0	24
146	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, Tj ETQq0 0 0 rgBT /Overlook, 10 Tf 50 Oncology, 2020, 38, 3081-3081.	1.6	24
147	Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. <i>Yonsei Medical Journal</i> , 1998, 39, 27.	2.2	23
148	Correlation of tissue and blood plasminogen activation system in breast cancer. <i>Cancer Letters</i> , 2000, 150, 137-145.	7.2	23
149	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 797-805.	2.3	23
150	Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. <i>Clinical Cancer Research</i> , 2005, 11, 79-86.	7.0	23
151	Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. <i>International Journal of Oncology</i> , 2003, 22, 741.	3.3	22
152	Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer. <i>Archives of Surgery</i> , 2008, 143, 1091.	2.2	22
153	Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. <i>Cancer Science</i> , 2010, 101, 2200-2206.	3.9	22
154	High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. <i>Oncology Letters</i> , 2012, 4, 123-130.	1.8	22
155	Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. <i>Pathology</i> , 2014, 46, 316-324.	0.6	22
156	Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanamide, a novel histone deacetylase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 233-238.	2.1	21
157	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010, 28, 650-658.	2.6	21
158	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277.	7.0	21
159	The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. <i>Yonsei Medical Journal</i> , 1992, 33, 137.	2.2	20
160	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , 2012, 30, 672-680.	2.6	20
161	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , 2013, 107, 613-618.	1.7	20
162	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281.	7.0	20

#	ARTICLE	IF	CITATIONS
163	A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. Journal of Clinical Oncology, 2014, 32, 2514-2514.	1.6	20
164	Relationship between p53 Overexpression and Gastric Cancer Progression. Oncology, 1997, 54, 166-170.	1.9	19
165	Early Postoperative Intraperitoneal Chemotherapy with Mitomycin C, 5-Fluorouracil and Cisplatin for Advanced Gastric Cancer. Oncology, 2001, 60, 24-30.	1.9	19
166	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Gastric Cancer, 2019, 22, 1153-1163.	5.3	19
167	A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 315-321.	2.3	18
168	A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: The significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. Scandinavian Journal of Gastroenterology, 2010, 45, 217-225.	1.5	18
169	Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. Supportive Care in Cancer, 2012, 20, 2177-2182.	2.2	18
170	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf treated with chemotherapy. Investigational New Drugs, 2012, 30, 1501-1510.	2.6	18
171	Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. Annals of Surgical Oncology, 2013, 20, 2615-2624.	1.5	18
172	Prognosis of pN3 Stage Gastric Cancer. Cancer Research and Treatment, 2009, 41, 73.	3.0	18
173	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Research and Treatment, 2019, 51, 1-11.	3.0	17
174	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Investigational New Drugs, 2021, 39, 1366-1374.	2.6	17
175	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.. Journal of Clinical Oncology, 2019, 37, TPS4146-TPS4146.	1.6	17
176	Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. Cancer Letters, 1997, 118, 37-46.	7.2	16
177	In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Genomics, 2009, 93, 52-61.	2.9	16
178	Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Oncology Reports, 2011, 25, 717-27.	2.6	16
179	Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?. Medicine (United States), 2015, 94, e1259.	1.0	16
180	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Annals of Nuclear Medicine, 2016, 30, 279-286.	2.2	16

#	ARTICLE	IF	CITATIONS
181	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 61837-61845.	1.8	16
182	MET in gastric cancer with liver metastasis: The relationship between <i>MET</i> amplification and Met overexpression in primary stomach tumors and liver metastasis. <i>Journal of Surgical Oncology</i> , 2018, 117, 1679-1686.	1.7	16
183	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , 2018, 18, 158.	2.6	16
184	Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 84-91.	2.8	16
185	Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2021, 144, 49-60.	2.8	16
186	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment</i> , 2021, 53, 323-329.	3.0	16
187	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β 2 and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. <i>Targeted Oncology</i> , 2021, 16, 447-459.	3.6	16
188	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS252-TPS252.	1.6	16
189	Pregnancy-Associated Osteoporosis. <i>Yonsei Medical Journal</i> , 1988, 29, 286.	2.2	15
190	Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998, 49, 41-50.	2.5	15
191	Lack of Correlation Between P-glycoprotein and Chemotherapy Resistance in Nasal NK/T-cell Lymphomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1857-1864.	1.3	15
192	A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer. <i>Oncology</i> , 2006, 70, 63-70.	1.9	15
193	Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer. <i>Journal of Psychosomatic Research</i> , 2014, 77, 76-80.	2.6	15
194	Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. <i>Oncology</i> , 2015, 88, 147-156.	1.9	15
195	Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 6171-6180.	1.1	15
196	Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1108-e1114.	3.7	15
197	Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> . 2021, 189, 665-676.	2.5	15
198	A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2514-2514.	1.6	15

#	ARTICLE	IF	CITATIONS
199	Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. PLoS ONE, 2012, 7, e45127.	2.5	15
200	Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. BMC Bioinformatics, 2008, 9, 283.	2.6	14
201	Subtelomeric DNA methylation and telomere length in human cancer cells. Cancer Letters, 2009, 281, 82-91.	7.2	14
202	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anti-Cancer Drugs, 2011, 22, 801-810.	1.4	14
203	Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis. Japanese Journal of Clinical Oncology, 2011, 41, 1344-1350.	1.3	14
204	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. Oncology, 2019, 96, 59-69.	1.9	14
205	Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.. Journal of Clinical Oncology, 2019, 37, 4009-4009.	1.6	14
206	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 851-860.	3.0	14
207	Severe Hypothyroidism Induced by Thyroid Metastasis of Colon Adenocarcinoma: A Case Report and Review of the Literature. Endocrine Journal, 2006, 53, 339-343.	1.6	13
208	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 157-165.	2.3	13
209	G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Letters, 2009, 277, 155-163.	7.2	13
210	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 3938-3945.	1.5	13
211	A novel <i>TP53-KPNA3</i> translocation defines a de novo treatment-resistant clone in osteosarcoma. Journal of Physical Education and Sports Management, 2016, 2, a000992.	1.2	13
212	A Comparative Study of Intravenous Granisetron Versus Intravenous and Oral Ondansetron in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 569-572.	1.3	13
213	Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1 ⁺ positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.. Journal of Clinical Oncology, 2020, 38, 427-427.	1.6	13
214	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget, 2017, 8, 31169-31179.	1.8	13
215	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. Cancer Research and Treatment, 1970, 47, 9-17.	3.0	12
216	Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2008, 62, 263-270.	2.3	12

#	ARTICLE	IF	CITATIONS
217	Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. <i>BMC Cancer</i> , 2008, 8, 8.	2.6	12
218	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2051-2059.	2.5	12
219	Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 484-489.	1.3	12
220	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222.	3.0	12
221	Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. <i>Cancer Gene Therapy</i> , 2004, 11, 532-538.	4.6	11
222	A Pilot Study of Trans-Arterial Injection of ¹⁶⁶ Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2005, 46, 799.	2.2	11
223	Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast. <i>Human Pathology</i> , 2009, 40, 98-107.	2.0	11
224	Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. <i>Journal of Surgical Oncology</i> , 2010, 102, 454-461.	1.7	11
225	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , 2013, 31, 1-13.	2.6	11
226	Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. <i>Journal of Radiation Research</i> , 2013, 54, 52-60.	1.6	11
227	PINCH2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015, 136, 2273-2283.	5.1	11
228	Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study. <i>Supportive Care in Cancer</i> , 2020, 28, 1265-1275.	2.2	11
229	p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. <i>Biochemical Pharmacology</i> , 2021, 183, 114320.	4.4	11
230	Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4031-4031.	1.6	11
231	A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3056-3056.	1.6	11
232	Male breast cancer: a 20-year review of 16 cases at Yonsei University. <i>Yonsei Medical Journal</i> , 1990, 31, 242.	2.2	10
233	Novel and simple transformation algorithm for combining microarray data sets. <i>BMC Bioinformatics</i> , 2007, 8, 218.	2.6	10
234	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 75-81.	2.3	10

#	ARTICLE	IF	CITATIONS
235	Variation of the 3â€² telomeric overhang lengths in human cells. <i>Cancer Letters</i> , 2008, 264, 107-118.	7.2	10
236	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , 2021, 10, 3249-3260.	2.8	10
237	Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4062-4062.	1.6	10
238	First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4534-4534.	1.6	10
239	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.. <i>Journal of Clinical Oncology</i> , 2020, 38, 383-383.	1.6	10
240	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015, 47, 781-789.	3.0	10
241	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 819-831.	3.0	10
242	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 72-86.	1.4	10
243	Comparison of adjuvant radiotherapy and chemoradiotherapy following surgery in stage IE and IIE primary gastrointestinal tract non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , 1990, 31, 144.	2.2	9
244	The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck. <i>Cancer</i> , 2001, 91, 2343-2352.	4.1	9
245	The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. <i>International Journal of Molecular Medicine</i> , 2004, 13, 17.	4.0	9
246	Treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 258-269.	1.1	9
247	Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. <i>International Journal of Molecular Medicine</i> , 2013, 31, 1202-1208.	4.0	9
248	Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. <i>Biochemical Pharmacology</i> , 2017, 138, 163-173.	4.4	9
249	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
250	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4523-4523.	1.6	9
251	An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions. <i>Cancer Research and Treatment</i> , 2007, 39, 74.	3.0	9
252	Point mutation at codon 12 of the c-Ha-ras gene in human gastric cancers.. <i>Journal of Korean Medical Science</i> , 1992, 7, 110.	2.5	8

#	ARTICLE	IF	CITATIONS
253	A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 313-320.	2.3	8
254	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 361-366.	0.6	8
255	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 265-272.	1.1	8
256	LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 230-230.	1.6	8
257	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 38389-38398.	1.8	8
258	Coexisting mycosis fungoides and Hodgkin's disease as a composite lymphoma: a case report. <i>Yonsei Medical Journal</i> , 1991, 32, 362.	2.2	7
259	A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. <i>Journal of Bioscience and Bioengineering</i> , 2009, 108, 252-258.	2.2	7
260	Increments of α -dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. <i>Journal of Surgical Oncology</i> , 2009, 100, 459-465.	1.7	7
261	A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 357-363.	2.6	7
262	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 799-808.	2.3	7
263	Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 204-209.	1.1	7
264	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	7
265	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , 2019, 140, 143-149.	0.6	7
266	Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study. , 2021, , .		7
267	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	5.3	7
268	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH,) Tj ETQq0 0 0 1gBT /Overlock 10 Tf		
269	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4513-4513.	1.6	7
270	Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2022, 14, 2659.	3.7	7

#	ARTICLE	IF	CITATIONS
271	Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Medical Journal, 1991, 32, 126.	2.2	6
272	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. Cancer Letters, 2008, 270, 269-276.	7.2	6
273	Novel biomarker candidates for gastric cancer. Oncology Reports, 2008, , .	2.6	6
274	Genetic and Epigenetic Marker-Based DNA Test of Stool Is a Promising Approach for Colorectal Cancer Screening. Yonsei Medical Journal, 2009, 50, 331.	2.2	6
275	A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status. Oncology, 2009, 77, 349-357.	1.9	6
276	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemotherapy and Pharmacology, 2009, 63, 919-927.	2.3	6
277	S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer, 2013, 13, 583.	2.6	6
278	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Oncology Letters, 2017, 14, 2385-2392.	1.8	6
279	Regulation of proliferation and invasion by the <scp>IGF</scp> signalling pathway in Epsteinâ€Barr virusâ€positive gastric cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 5899-5908.	3.6	6
280	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. Journal of Clinical Oncology, 2015, 33, 10565-10565.	1.6	6
281	Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).. Journal of Clinical Oncology, 2018, 36, 4036-4036.	1.6	6
282	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. Journal of Clinical Oncology, 2020, 38, TPS3145-TPS3145.	1.6	6
283	Prognostic significance of Tâ€cellâ€inflamed gene expression profile and PDâ€L1 expression in patients with esophageal cancer. Cancer Medicine, 2021, 10, 8365-8376.	2.8	6
284	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 4540-4540.	1.6	6
285	Pleural Aspergillosis. Yonsei Medical Journal, 1988, 29, 84.	2.2	5
286	P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer. Yonsei Medical Journal, 1996, 37, 397.	2.2	5
287	Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. International Journal of Molecular Medicine, 2005, 16, 857.	4.0	5
288	Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial. Investigational New Drugs, 2014, 32, 753-761.	2.6	5

#	ARTICLE	IF	CITATIONS
289	Safety and preliminary antitumor activity of the transforming growth factor beta (TGF- β 2) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, e16505-e16505.	1.6	5
290	Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. Cancer Research and Treatment, 2019, 51, 1578-1588.	3.0	5
291	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 712-712.	1.6	5
292	Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. Oncology Reports, 2007, , .	2.6	4
293	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 991-999.	2.3	4
294	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. Investigational New Drugs, 2017, 35, 773-781.	2.6	4
295	Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2021, 39, TPS264-TPS264.	1.6	4
296	MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, TPS4134-TPS4134.	1.6	4
297	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.. Journal of Clinical Oncology, 2020, 38, TPS463-TPS463.	1.6	4
298	A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and Taxane-based Neoadjuvant Chemotherapy: A Case Report. Cancer Research and Treatment, 2007, 39, 134.	3.0	4
299	Methylation Status of Lamin A/C in Gastric Cancer Cell Lines. Hepato-Gastroenterology, 2012, 59, 1313-8.	0.5	4
300	Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen. Yonsei Medical Journal, 1990, 31, 74.	2.2	3
301	An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma. Yonsei Medical Journal, 1998, 39, 463.	2.2	3
302	Systematic analysis of cDNA microarray-based CGH. International Journal of Molecular Medicine, 2006, 17, 261.	4.0	3
303	Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. Oncology Reports, 2006, 15, 749.	2.6	3
304	Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction. Yonsei Medical Journal, 2009, 50, 296.	2.2	3
305	Identification of significant regional genetic variations using continuous CNV values in aCGH data. Genomics, 2009, 94, 317-323.	2.9	3
306	A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 56-60.	1.3	3

#	ARTICLE	IF	CITATIONS
307	Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 141-143.	1.1	3
308	Inflammatory and Tumor Stimulating Responses after Laparoscopic Sigmoidectomy. Yonsei Medical Journal, 2011, 52, 635.	2.2	3
309	ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Biochemical Pharmacology, 2017, 123, 73-84.	4.4	3
310	Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 163, 255-262.	2.5	3
311	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. Journal of Clinical Oncology, 2019, 37, 8-8.	1.6	3
312	Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1-“positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.. Journal of Clinical Oncology, 2020, 38, e16586-e16586.	1.6	3
313	T-cell-“inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).. Journal of Clinical Oncology, 2019, 37, 26-26.	1.6	3
314	Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. Genomics and Informatics, 2020, 18, e37.	0.8	3
315	Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. Cellular Oncology (Dordrecht), 2021, 44, 1387-1403.	4.4	3
316	Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. International Journal of Molecular Medicine, 2002, 10, 251.	4.0	2
317	Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Breast Cancer Research and Treatment, 2007, 104, 31-37.	2.5	2
318	Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. International Journal of Oncology, 2009, 34, 837-46.	3.3	2
319	Standardized genetic alteration score and predicted score for predicting recurrence status of gastric cancer. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1501-1512.	2.5	2
320	Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 29-35.	1.3	2
321	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Investigational New Drugs, 2014, 32, 561-568.	2.6	2
322	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. European Journal of Cancer, 2019, 112, 20-28.	2.8	2
323	High level of urokinase-“type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer, 1997, 79, 878-883.	4.1	2
324	Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2020, 38, TPS468-TPS468.	1.6	2

#	ARTICLE	IF	CITATIONS
325	Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH. International Journal of Molecular Medicine, 2007, 19, 901-8.	4.0	2
326	Should all the N3 lymph nodes group metastasis be regarded as distant metastasis (M1) in curatively resected gastric cancer? Yonsei Medical Journal, 1992, 33, 143.	2.2	1
327	Immunohistochemical Expression of c-erbB2, c-erbB3 and c-erbB4 Protein in Breast Cancer. Journal of Korean Breast Cancer Society, 1998, 1, 215.	0.1	1
328	Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion before and during cisplatin chemotherapy in patients with intrathoracic malignancy. Tuberculosis and Respiratory Diseases, 1999, 46, 811.	0.2	1
329	Statistical Issues in the Search for Biomarkers of Colorectal Cancer Using Microarray Experiments. Wiley Series in Probability and Statistics, 2006, , 333-343.	0.0	1
330	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. Acta Oncologica, 2007, 46, 547-549.	1.8	1
331	Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-amplified RNA. International Journal of Molecular Medicine, 0, , .	4.0	1
332	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. International Journal of Oncology, 2009, 34, 787-96.	3.3	1
333	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. BMC Cancer, 2012, 12, 471.	2.6	1
334	Identification of Natural Products as Novel PI3K ^{Î²} Inhibitors Through Pharmacophore-based Virtual Screening. Bulletin of the Korean Chemical Society, 2018, 39, 294-299.	1.9	1
335	Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells. Frontiers in Oncology, 2020, 10, 562284.	2.8	1
336	Abstract 945: Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells. , 2021, , .		1
337	Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).. Journal of Clinical Oncology, 2012, 30, 259-259.	1.6	1
338	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 492-492.	1.6	1
339	An update on the randomized phase III POST trial: S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer.. Journal of Clinical Oncology, 2016, 34, 4042-4042.	1.6	1
340	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, 90-90.	1.6	1
341	Prospective validation of a serum miRNA panel for early detection of gastric cancer.. Journal of Clinical Oncology, 2019, 37, 4065-4065.	1.6	1
342	Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports. Cancer Research and Treatment, 2006, 38, 184.	3.0	1

#	ARTICLE	IF	CITATIONS
343	PD-L1 expression in patients with metastatic gastric cancer in South Korea.. Journal of Clinical Oncology, 2017, 35, 1571-1571.	1.6	1
344	CTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro-Oncology, 2021, 23, vi73-vi74.	1.2	1
345	Clinical and Mammographic Findings of Primary Lymphoma of the Breast. Journal of the Korean Radiological Society, 1997, 37, 177.	0.0	0
346	Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH. International Journal of Molecular Medicine, 2007, 19, 901.	4.0	0
347	Prediction of S-1-induced anemia. Gastric Cancer, 2009, 12, 23-30.	5.3	0
348	Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. Cancer Chemotherapy and Pharmacology, 2010, 66, 425-431.	2.3	0
349	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. AAPS Journal, 2018, 20, 72.	4.4	0
350	Abstract 1090: Overcoming trastuzumab resistance using trastuzumab deruxtecan (T-DXd), a HER2 targeting antibody drug conjugate, in HER2 amplified gastric cancer. , 2021, , .		0
351	Abstract 2055: Evaluation of DNA damage repair gene alterations, microsatellite instability status, and tumor mutational burden as predictive biomarkers of olaparib sensitivity in gastric cancer. , 2021, , .		0
352	Abstract 2973: Establishment of organoids and patient derived cancer cell lines from gastric cancer body fluids as preclinical models for personalized therapy. , 2021, , .		0
353	S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer. Korean Journal of Internal Medicine, 2008, 23, 37.	1.7	0
354	Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer.. Journal of Clinical Oncology, 2012, 30, 3606-3606.	1.6	0
355	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14652-e14652.	1.6	0
356	Mucinous histology to predict disease-free survival in microsatellite stable stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.. Journal of Clinical Oncology, 2012, 30, e14084-e14084.	1.6	0
357	The effect of delay of adjuvant chemotherapy on survival in patients with resected stage II and III gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15144-e15144.	1.6	0
358	Clinicopathologic features predicting HER2 overexpression in gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15098-e15098.	1.6	0
359	Role of Mammography in Evaluating Residual Cancer after Neo-adjuvant Chemotherapy of Locally Advanced Breast Carcinoma: Compared with Clinical Examination. Journal of the Korean Radiological Society, 1997, 36, 1081.	0.0	0
360	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. Journal of Clinical Oncology, 2014, 32, e22164-e22164.	1.6	0

#	ARTICLE	IF	CITATIONS
361	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15020-e15020.	1.6	0
362	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. Journal of Clinical Oncology, 2015, 33, 11010-11010.	1.6	0
363	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4113-4113.	1.6	0
364	Waun Ki Hong, MD, D.M.Sc (Hon) (1942â€“2019): A Mentor Who Left Behind a Legacy for Generations to Come. Yonsei Medical Journal, 2020, 61, 557.	2.2	0
365	409â€¦Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. , 2021, 9, A440-A440.		0